^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAY 2862789

    i
    Other names: BAY 2862789, BAY2862789, BAY-2862789
    Associations

    News

    Trials
    Company:
    Bayer, German Cancer Research Center
    Drug class:
    DGKA inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=45, Completed, Bayer | N=69 --> 45 | Active, not recruiting --> Completed
    Trial completion • Enrollment change • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    BAY 2862789
    9ms
    A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=69, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    BAY 2862789
    12ms
    A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=69, Recruiting, Bayer | N=102 --> 69 | Trial completion date: Mar 2027 --> Jul 2025 | Trial primary completion date: Mar 2027 --> Jul 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    BAY 2862789
    1year
    DGKalpha inhibitor BAY 2862789 FiH trial in advanced solid cancers (ChiCTR2400093606)
    P1, N=81, Jilin Cancer Hospital; Jilin Cancer Hospital
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • CD4 (CD4 Molecule)
    |
    EGFR mutation • MSI-H/dMMR • BRAF positive
    |
    FoundationOne® CDx • Guardant360® CDx • Ventana MMR RxDx Panel • OncoMate™ MSI
    |
    BAY 2862789
    over1year
    A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=102, Recruiting, Bayer | Trial primary completion date: Jul 2025 --> Mar 2027
    Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    BAY 2862789
    almost2years
    A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=102, Recruiting, Bayer | N=74 --> 102
    Enrollment change • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    BAY 2862789
    2years
    A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=74, Recruiting, Bayer | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Feb 2026 --> Jul 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    BAY 2862789
    over2years
    A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=74, Recruiting, Bayer | Trial completion date: Apr 2026 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK mutation
    |
    BAY 2862789
    over2years
    A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=74, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    EGFR mutation • ALK mutation
    |
    BAY 2862789
    almost3years
    A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=74, Not yet recruiting, Bayer
    New P1 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    EGFR mutation • ALK mutation
    |
    BAY 2862789